JAZZ PHARMACEUTICALS PLC (JAZZ)
IE00B4Q5ZN47 - Common Stock
JAZZ gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. JAZZ scores excellent on profitability, but there are some minor concerns on its financial health. JAZZ is valued quite cheap, while showing a decent growth score. This is a good combination! This makes JAZZ very considerable for value investing!
1. Profitability
1.1 Basic Checks
JAZZ had positive earnings in the past year.
JAZZ had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
In the past 5 years JAZZ always reported a positive cash flow from operatings.
1.2 Ratios
JAZZ's Return On Assets of 3.78% is amongst the best of the industry. JAZZ outperforms 86.39% of its industry peers.
With an excellent Return On Equity value of 11.10%, JAZZ belongs to the best of the industry, outperforming 89.53% of the companies in the same industry.
JAZZ has a Return On Invested Capital of 4.95%. This is amongst the best in the industry. JAZZ outperforms 81.68% of its industry peers.
JAZZ had an Average Return On Invested Capital over the past 3 years of 3.02%. This is significantly below the industry average of 43.18%.
The 3 year average ROIC (3.02%) for JAZZ is below the current ROIC(4.95%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.78% | ||
| ROE | 11.1% | ||
| ROIC | 4.95% |
ROA(3y)-0.37%
ROA(5y)2.4%
ROE(3y)-1.49%
ROE(5y)3.77%
ROIC(3y)3.02%
ROIC(5y)4.82%
1.3 Margins
JAZZ has a better Profit Margin (11.60%) than 87.43% of its industry peers.
JAZZ's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 17.62%, JAZZ belongs to the best of the industry, outperforming 85.34% of the companies in the same industry.
JAZZ's Operating Margin has declined in the last couple of years.
JAZZ has a better Gross Margin (89.37%) than 92.67% of its industry peers.
JAZZ's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.62% | ||
| PM (TTM) | 11.6% | ||
| GM | 89.37% |
OM growth 3Y-6.66%
OM growth 5Y-12.64%
PM growth 3Y2.34%
PM growth 5Y-14.48%
GM growth 3Y-1.83%
GM growth 5Y-1.08%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so JAZZ is destroying value.
Compared to 1 year ago, JAZZ has less shares outstanding
The number of shares outstanding for JAZZ has been increased compared to 5 years ago.
The debt/assets ratio for JAZZ has been reduced compared to a year ago.
2.2 Solvency
JAZZ has an Altman-Z score of 1.50. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
JAZZ has a better Altman-Z score (1.50) than 64.40% of its industry peers.
The Debt to FCF ratio of JAZZ is 5.55, which is a neutral value as it means it would take JAZZ, 5.55 years of fcf income to pay off all of its debts.
JAZZ has a better Debt to FCF ratio (5.55) than 87.43% of its industry peers.
A Debt/Equity ratio of 1.46 is on the high side and indicates that JAZZ has dependencies on debt financing.
JAZZ has a worse Debt to Equity ratio (1.46) than 76.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 5.55 | ||
| Altman-Z | 1.5 |
ROIC/WACC0.81
WACC6.08%
2.3 Liquidity
JAZZ has a Current Ratio of 4.26. This indicates that JAZZ is financially healthy and has no problem in meeting its short term obligations.
JAZZ has a better Current ratio (4.26) than 62.30% of its industry peers.
A Quick Ratio of 3.74 indicates that JAZZ has no problem at all paying its short term obligations.
JAZZ has a better Quick ratio (3.74) than 60.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.26 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
JAZZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.22%, which is quite impressive.
Measured over the past 5 years, JAZZ shows a small growth in Earnings Per Share. The EPS has been growing by 6.00% on average per year.
JAZZ shows a small growth in Revenue. In the last year, the Revenue has grown by 5.23%.
The Revenue has been growing by 15.19% on average over the past years. This is quite good.
EPS 1Y (TTM)48.22%
EPS 3Y13.68%
EPS 5Y6%
EPS Q2Q%36.57%
Revenue 1Y (TTM)5.23%
Revenue growth 3Y17.5%
Revenue growth 5Y15.19%
Sales Q2Q%8.52%
3.2 Future
The Earnings Per Share is expected to grow by 8.31% on average over the next years. This is quite good.
The Revenue is expected to grow by 5.73% on average over the next years.
EPS Next Y13.27%
EPS Next 2Y10.18%
EPS Next 3Y7.79%
EPS Next 5Y8.31%
Revenue Next Year5.42%
Revenue Next 2Y6.12%
Revenue Next 3Y5.51%
Revenue Next 5Y5.73%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 6.27, the valuation of JAZZ can be described as very cheap.
Based on the Price/Earnings ratio, JAZZ is valued cheaply inside the industry as 94.76% of the companies are valued more expensively.
JAZZ is valuated cheaply when we compare the Price/Earnings ratio to 27.73, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 5.53, which indicates a rather cheap valuation of JAZZ.
Based on the Price/Forward Earnings ratio, JAZZ is valued cheaply inside the industry as 95.81% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.83. JAZZ is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.27 | ||
| Fwd PE | 5.53 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, JAZZ is valued cheaper than 90.58% of the companies in the same industry.
95.29% of the companies in the same industry are more expensive than JAZZ, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.75 | ||
| EV/EBITDA | 7.77 |
4.3 Compensation for Growth
JAZZ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.47
PEG (5Y)1.05
EPS Next 2Y10.18%
EPS Next 3Y7.79%
5. Dividend
5.1 Amount
No dividends for JAZZ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
JAZZ PHARMACEUTICALS PLC
NASDAQ:JAZZ (12/20/2024, 8:19:44 PM)
After market: 122.97 0 (0%)122.97
+0.12 (+0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners96.94%
Inst Owner Change1.34%
Ins Owners2.36%
Ins Owner Change1.11%
Market Cap7.43B
Analysts81.6
Price Target180.54 (46.82%)
Short Float %7.25%
Short Ratio7.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.36%
Min EPS beat(2)8.88%
Max EPS beat(2)17.85%
EPS beat(4)2
Avg EPS beat(4)-3.87%
Min EPS beat(4)-37.13%
Max EPS beat(4)17.85%
EPS beat(8)2
Avg EPS beat(8)-18.7%
EPS beat(12)5
Avg EPS beat(12)-10.98%
EPS beat(16)8
Avg EPS beat(16)-6.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.1%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)-0.02%
Revenue beat(4)0
Avg Revenue beat(4)-2.1%
Min Revenue beat(4)-7.3%
Max Revenue beat(4)-0.02%
Revenue beat(8)0
Avg Revenue beat(8)-1.84%
Revenue beat(12)2
Avg Revenue beat(12)-1.68%
Revenue beat(16)3
Avg Revenue beat(16)-1.36%
PT rev (1m)-0.95%
PT rev (3m)2.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)0.88%
EPS NY rev (3m)3.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.31%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.27 | ||
| Fwd PE | 5.53 | ||
| P/S | 1.86 | ||
| P/FCF | 6.75 | ||
| P/OCF | 6.38 | ||
| P/B | 1.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.77 |
EPS(TTM)19.61
EY15.95%
EPS(NY)22.24
Fwd EY18.09%
FCF(TTM)18.23
FCFY14.82%
OCF(TTM)19.27
OCFY15.67%
SpS66.05
BVpS69
TBVpS-45.95
PEG (NY)0.47
PEG (5Y)1.05
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.78% | ||
| ROE | 11.1% | ||
| ROCE | 6.27% | ||
| ROIC | 4.95% | ||
| ROICexc | 6.46% | ||
| ROICexgc | 33.51% | ||
| OM | 17.62% | ||
| PM (TTM) | 11.6% | ||
| GM | 89.37% | ||
| FCFM | 27.6% |
ROA(3y)-0.37%
ROA(5y)2.4%
ROE(3y)-1.49%
ROE(5y)3.77%
ROIC(3y)3.02%
ROIC(5y)4.82%
ROICexc(3y)3.45%
ROICexc(5y)6.29%
ROICexgc(3y)24.22%
ROICexgc(5y)39.58%
ROCE(3y)3.82%
ROCE(5y)6.1%
ROICexcg growth 3Y-9.45%
ROICexcg growth 5Y-18.29%
ROICexc growth 3Y-15.61%
ROICexc growth 5Y-12.76%
OM growth 3Y-6.66%
OM growth 5Y-12.64%
PM growth 3Y2.34%
PM growth 5Y-14.48%
GM growth 3Y-1.83%
GM growth 5Y-1.08%
F-Score7
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 5.55 | ||
| Debt/EBITDA | 4.49 | ||
| Cap/Depr | 9.66% | ||
| Cap/Sales | 1.57% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.98% | ||
| Profit Quality | 237.89% | ||
| Current Ratio | 4.26 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z | 1.5 |
F-Score7
WACC6.08%
ROIC/WACC0.81
Cap/Depr(3y)31.37%
Cap/Depr(5y)55.93%
Cap/Sales(3y)5.4%
Cap/Sales(5y)8.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.22%
EPS 3Y13.68%
EPS 5Y6%
EPS Q2Q%36.57%
EPS Next Y13.27%
EPS Next 2Y10.18%
EPS Next 3Y7.79%
EPS Next 5Y8.31%
Revenue 1Y (TTM)5.23%
Revenue growth 3Y17.5%
Revenue growth 5Y15.19%
Sales Q2Q%8.52%
Revenue Next Year5.42%
Revenue Next 2Y6.12%
Revenue Next 3Y5.51%
Revenue Next 5Y5.73%
EBIT growth 1Y265.16%
EBIT growth 3Y9.68%
EBIT growth 5Y0.62%
EBIT Next Year7.73%
EBIT Next 3Y5.56%
EBIT Next 5Y8.56%
FCF growth 1Y11.97%
FCF growth 3Y26.33%
FCF growth 5Y9.47%
OCF growth 1Y5.14%
OCF growth 3Y6.67%
OCF growth 5Y6.45%